The safety of current and emerging therapies for multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma treatment has advanced with novel targeted agents.
• These agents demonstrate high efficacy but possess distinct toxicity profiles.
• A comprehensive review of safety data is essential for clinical decision-making.

Purpose of the Study:

• To review the safety and efficacy of current and emerging multiple myeloma therapies.
• To highlight the toxicity profiles of various therapeutic classes.
• To inform clinical practice regarding optimal treatment selection.

Main Methods:

• Literature review of safety and efficacy data for multiple myeloma agents.
• Inclusion of alkylators, proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, nuclear export inhibitors, and histone deacetylase inhibitors.
• Review of emerging therapies including BCL2 inhibitors and BCMA-targeted immunotherapies (CAR T-cells, bispecific antibodies, antibody-drug conjugates).

Main Results:

• Novel targeted agents provide significant therapeutic benefits in multiple myeloma.
• Each class of agents, including emerging immunotherapies, has a unique toxicity profile.
• Understanding these profiles is key to managing treatment-related adverse events.

Conclusions:

• The evolving landscape of multiple myeloma therapy necessitates a thorough understanding of agent safety.
• Key considerations include treatment sequencing, stem cell transplantation, maintenance therapy, and immunotherapy timing.
• Personalized selection of therapies based on toxicity profiles is paramount for effective patient management.